Whitebox Advisors LLC reduced its stake in shares of Allergan PLC (NYSE:AGN) by 26.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,849 shares of the company’s stock after selling 18,351 shares during the period. Allergan PLC comprises 0.3% of Whitebox Advisors LLC’s portfolio, making the stock its 29th largest position. Whitebox Advisors LLC’s holdings in Allergan PLC were worth $11,751,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the stock. AMP Capital Investors Ltd raised its stake in shares of Allergan PLC by 4.9% in the first quarter. AMP Capital Investors Ltd now owns 163,096 shares of the company’s stock valued at $44,844,000 after buying an additional 7,588 shares during the period. Arizona State Retirement System raised its stake in shares of Allergan PLC by 0.9% in the first quarter. Arizona State Retirement System now owns 108,577 shares of the company’s stock valued at $29,102,000 after buying an additional 1,000 shares during the period. Intermede Investment Partners Ltd bought a new stake in shares of Allergan PLC during the second quarter valued at about $37,790,000. LPL Financial LLC raised its stake in shares of Allergan PLC by 21.5% in the first quarter. LPL Financial LLC now owns 130,911 shares of the company’s stock valued at $30,976,000 after buying an additional 23,160 shares during the period. Finally, Alpine Partners VI LLC raised its stake in shares of Allergan PLC by 109.6% in the first quarter. Alpine Partners VI LLC now owns 19,548 shares of the company’s stock valued at $5,239,000 after buying an additional 10,223 shares during the period. Hedge funds and other institutional investors own 85.19% of the company’s stock.
Allergan PLC (NYSE:AGN) traded down 2.94% during midday trading on Thursday, hitting $230.80. The stock had a trading volume of 4,369,244 shares. The stock has a 50-day moving average price of $243.59 and a 200 day moving average price of $241.22. Allergan PLC has a one year low of $195.50 and a one year high of $322.68. The firm has a market cap of $91.39 billion, a PE ratio of 21.97 and a beta of 0.73.
Allergan PLC (NYSE:AGN) last posted its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The business earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the firm earned $4.41 earnings per share. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. On average, analysts predict that Allergan PLC will post $14.00 earnings per share for the current year.
Several analysts recently issued reports on AGN shares. Mizuho upgraded shares of Allergan PLC from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $248.00 to $318.00 in a report on Friday, August 19th. Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $288.87 price objective on the stock in a report on Monday, August 22nd. Goldman Sachs Group Inc. restated a “buy” rating and issued a $300.00 price objective on shares of Allergan PLC in a report on Tuesday. Bank of America Corp. set a $294.00 price objective on shares of Allergan PLC and gave the company a “buy” rating in a report on Tuesday, September 20th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Allergan PLC in a report on Friday, June 10th. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $309.68.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.